Rotavirus Vaccine Phase III Trials May Require 60,000 - 100,000 Patients
Executive Summary
Rotavirus vaccine Phase III studies may require between 60,000 and 100,000 patients to address rare adverse event risks, Thomas Fleming, PhD, University of Washington, said during the Vaccines & Related Biological Products Advisory Committee meeting May 11.